The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N- cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3, 3-dimethylpentan-2-ol (BU08028): Characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 3, 2011, Pages 952-961

  Khroyan, Taline V ^a   Polgar, Willma E ^a   Cami Kobeci, Gerta ^b   Husbands, Stephen M ^b   Zaveri, Nurulain T ^c   Toll, Lawrence ^a  

^a SRI INTERNATIONAL   (United States)

^b University of Bath   (United Kingdom)

^c Astraea Therapeutics Inc   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 [N CYCLOPROPYLMETHYL 4,5 EPOXY 6,14 ETHANO 3 HYDROXY 6 METHOXYMORPHINAN 7 YL] 3,3 DIMETHYLPENTAN 2 OL; 7 [4 (2,6 DICHLOROPHENYL) 1 PIPERIDINYLMETHYL] 6,7,8,9 TETRAHYDRO 1 METHYL 5H BENZOCYCLOHEPTEN 5 OL; 7 [[4 (2,6 DICHLOROPHENYL)PIPERIDIN 1 YL]METHYL] 1 METHYL 6,7,8,9 TETRAHYDRO 5H BENZO[7]ANNULEN 5 OL; BU 08028; BUPRENORPHINE; DELTA OPIATE RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; ETORPHINE; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALOXONE; OPIATE AGONIST; SR 16435; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BEHAVIOR; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG BINDING; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; LOCOMOTION; MALE; MOUSE; NERVE STIMULATION; NONHUMAN; PAIN; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD;

ACUTE DISEASE; ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; CHO CELLS; COCAINE; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; HUMANS; LIGANDS; MALE; MICE; MICE, INBRED ICR; PAIN; PAIN MEASUREMENT; PROTEIN BINDING; RECEPTORS, OPIOID; REWARD;

EID: 79951994770     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.175620     Document Type: Article

References (40)

1. Bentley KW and Hardy DG (1967) Novel analgesics and molecular rearrangements in the morphine-thebaine group. 3. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of N-allylnormorphine and -norcodeine. J Am Chem Soc 89:3281-3292.
2. Brown EE, Finlay JM, Wong JT, Damsma G, and Fibiger HC (1991) Behavioral and neurochemical interactions between cocaine and buprenorphine: implications for the pharmacotherapy of cocaine abuse. J Pharmacol Exp Ther 256:119-126.
3. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
4. Ciccocioppo R, Economidou D, Fedeli A, and Massi M (2003) The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats. Physiol Behav 79:121-128. (Pubitemid 36734836)
5. Ciccocioppo R, Economidou D, Rimondini R, Sommer W, Massi M, and Heilig M (2007) Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol Psychiatry 61:4-12. (Pubitemid 44855733)
6. Ciccocioppo R, Panocka I, Polidori C, Regoli D, and Massi M (1999) Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacology 141:220-224. (Pubitemid 29200175)
7. Cowan A, Lewis JW, and Macfarlane IR (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537-545. (Pubitemid 8149539)
8. Dooley CT, Spaeth CG, Berzetei-Gurske IP, Craymer K, Adapa ID, Brandt SR, Houghten RA, and Toll L (1997) Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J Pharmacol Exp Ther 283:735-741. (Pubitemid 27514634)
9. Grundt P, Martinez-Bermejo F, Lewis JW, and Husbands SM (2003) Formic acid catalyzed rearrangement of thevinols (=4,5-epoxy-3,6-dimethoxy-α,17- dimethyl-6,14-ethenomorphinan-7-methanols) and their vinylogous analogues: effects of 5β-methyl substitution. Helv Chim Acta 86:2287-2298. (Pubitemid 37011952)
10. Ide S, Minami M, Satoh M, Uhl GR, Sora I, and Ikeda K (2004) Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in muopioid receptor knockout mice. Neuropsychopharmacology 29:1656-1663. (Pubitemid 39150107)
11. Jasinski DR, Pevnick JS, and Griffith JD (1978) Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 35:501-516. (Pubitemid 8337042)
12. Khroyan TV, Polgar WE, Jiang F, Zaveri NT, and Toll L (2009) NOP receptor activation attenuates antinociception induced by mixed NOP/mu-opioid receptor agonists. J Pharmacol Exp Ther 331:946-953.
13. Khroyan TV, Zaveri NT, Polgar WE, Orduna J, Olsen C, Jiang F, and Toll L (2007) SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice. J Pharmacol Exp Ther 320:934-943. (Pubitemid 46147978)
14. Kosten TA, Marby DW, and Nestler EJ (1991) Cocaine conditioned place preference is attenuated by chronic buprenorphine treatment. Life Sci 49:PL201-PL206.
15. Kotlińska J, Wichmann J, Legowska A, Rolka K, and Silberring J (2002) Orphanin FQ/nociceptin but not Ro 65-6570 inhibits the expression of cocaine-induced conditioned place preference. Behav Pharmacol 13:229-235. (Pubitemid 34816468)
16. Kuzmin A, Sandin J, Terenius L, and Ogren SO (2003) Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone. J Pharmacol Exp Ther 304:310-318. (Pubitemid 36008943)
17. Lattanzi R, Negri L, Giannini E, Schmidhammer H, Schutz J, and Improta G (2001) HS-599: a novel long acting opioid analgesic does not induce place-preference in rats. Br J Pharmacol 134:441-447. (Pubitemid 32989143)
18. Lewis JW (1985) Buprenorphine. Drug Alcohol Depend 14:363-372.
19. Lutfy K and Cowan A (2004) Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2:395-402. (Pubitemid 39276631)
20. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, et al. (2003) Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 23:10331-10337. (Pubitemid 37444610)
21. Lutfy K, Hossain SM, Khaliq I, and Maidment NT (2001) Orphanin FQ/nociceptin attenuates the development of morphine tolerance in rats. Br J Pharmacol 134: 529-534. (Pubitemid 32977897)
22. Marquez P, Baliram R, Kieffer BL, and Lutfy K (2007) The μ opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference. Neuropharmacology 52:1336-1341. (Pubitemid 46601527)
23. Marquez P, Nguyen AT, Hamid A, and Lutfy K (2008) The endogenous OFQ/N/ORL-1 receptor system regulates the rewarding effects of acute cocaine. Neuropharmacology 54:564-568.
24. Mello NK, Lukas SE, Mendelson JH, and Drieze J (1993) Naltrexone-buprenorphine interactions: effects on cocaine self-administration. Neuropsychopharmacology 9:211-224. (Pubitemid 23324321)
25. Mello NK, Mendelson JH, Bree MP, and Lukas SE (1989) Buprenorphine suppresses cocaine self-administration in rhesus monkeys. NIDA Res Monogr 95:333-334. (Pubitemid 20347226)
26. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, and Monsarrat B (1995) Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377:532-535.
27. Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, Lange WR, Contoreggi C, Johnson RE, and Fudala PJ (2004) Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 75:34-48.
28. Murphy NP, Lee Y, and Maidment NT (1999) Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res 832:168-170. (Pubitemid 29336175)
29. Placenza FM, Rajabi H, and Stewart J (2008) Effects of chronic buprenorphine treatment on levels of nucleus accumbens glutamate and on the expression of cocaine-induced behavioral sensitization in rats. Psychopharmacology 200:347-355.
30. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, and Civelli O (1995) Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270:792-794.
31. Rowlett JK, Gibson TR, and Bardo MT (1994) Dissociation of buprenorphine-induced locomotor sensitization and conditioned place preference in rats. Pharmacol Biochem Behav 49:241-245. (Pubitemid 24297285)
32. Sakoori K and Murphy NP (2004) Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice. Psychopharmacology 172:129-136. (Pubitemid 38388761)
33. Sorge RE, Rajabi H, and Stewart J (2005) Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and druginduced reinstatement. Neuropsychopharmacology 30:1681-1692. (Pubitemid 43086025)
34. Sorge RE and Stewart J (2006) The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration. Psychopharmacology 188:28-41. (Pubitemid 44268239)
35. Spagnolo B, Calo G, Polgar WE, Jiang F, Olsen CM, Berzetei-Gurske I, Khroyan TV, Husbands SM, Lewis JW, Toll L, et al. (2008) Activities of mixed NOP and mu-opioid receptor ligands. Br J Pharmacol 153:609-619. (Pubitemid 351199024)
36. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, et al. (1998) Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178:440-466.
37. Toll L, Khroyan TV, Polgar WE, Jiang F, Olsen C, and Zaveri NT (2009) Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/-μ opioid receptor ligands: implications for therapeutic applications. J Pharmacol Exp Ther 331:954-964.
38. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 47:848-854.
39. Zaveri N, Jiang F, Olsen C, Polgar W, and Toll L (2005) Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP. Aaps J 7:E345-E352. (Pubitemid 43078601)
40. Zhao RJ, Woo RS, Jeong MS, Shin BS, Kim DG, and Kim KW (2003) Orphanin FQ/nociceptin blocks methamphetamine place preference in rats. Neuroreport 14:2383-2385.